Services
- What is semaglutide?
- Semaglutide uses and indications
- Legal status in the UK
- Mechanism of action
- Price and how to buy online
- Available strengths and formulations
- Administration and dosing
- Clinical efficacy and trials
- Safety, side effects and tolerability
- Contraindications and interactions
- Generic versus branded semaglutide
- Buying without prescription
- Fast delivery and shipping
- Storage and handling
- FAQs and additional information
What is semaglutide?
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed to support glycaemic control in adults with type 2 diabetes and for weight management in obesity. As a synthetic peptide analogue of the human incretin hormone GLP-1, semaglutide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes a feeling of satiety. These combined actions can reduce blood glucose levels and encourage weight loss. Semaglutide is marketed under several brand names and is also available as a generic injection. Its introduction represents a significant advance in diabetes care and obesity management, and it is increasingly sought for off-label and weight-loss purposes.
Origin and development
Semaglutide was initially developed by Novo Nordisk and approved by regulatory agencies in 2017 for the treatment of type 2 diabetes. Since then, follow-on indications, including higher-dose regimens for chronic weight management, have been authorised in multiple jurisdictions. Research into semaglutide began with native GLP-1, which has a short half-life. Molecular modifications and the addition of albumin-binding side chains extended semaglutide’s half-life to approximately one week, allowing for once-weekly dosing in clinical practice.
Molecular structure
Semaglutide comprises 31 amino acids, including a substitution at position 8 (alanine to Aib) that protects against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). An attached C18 fatty acid chain increases albumin binding, resulting in prolonged plasma circulation and a favourable pharmacokinetic profile for once-weekly or once-daily administration, depending on the marketed formulation.
Semaglutide uses and indications
Semaglutide is indicated for the management of type 2 diabetes as an adjunct to diet and exercise to improve glycaemic control in adults. It is approved as a once-weekly subcutaneous injection in prefilled pens delivering 0.5 mg, 1 mg, or 2 mg per dose. A separate higher-dose format (2.4 mg weekly) is authorised for chronic weight management under specific clinical programmes. Semaglutide’s weight-loss indication is typically restricted to patients with a body mass index (BMI) ≥30 kg/m² (obesity) or ≥27 kg/m² with at least one weight-related comorbidity such as hypertension or dyslipidaemia.
Type 2 diabetes
In type 2 diabetes, semaglutide improves fasting and postprandial glycaemia by augmenting insulin secretion and reducing inappropriate glucagon release. Clinical studies demonstrate significant reductions in HbA1c (glycated haemoglobin) and body weight over 26 to 52 weeks when compared with placebo or active comparators. Its once-weekly regimen enhances adherence versus daily injections.
Obesity and weight management
Semaglutide 2.4 mg weekly has been approved for weight management in obese adults. In large randomised trials, patients on semaglutide achieved average weight losses exceeding 10% of baseline body weight, compared to placebo. It is prescribed alongside lifestyle interventions and is not a replacement for a balanced diet and regular exercise.
Off-label and investigational uses
Clinicians sometimes explore semaglutide in other contexts, including non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and cardiometabolic risk reduction. Ongoing studies will determine safety and efficacy in these areas.
Legal status in the UK
In the United Kingdom, all semaglutide products are classified as Prescription Only Medicines (POM). They cannot be supplied without a valid prescription from a qualified prescriber. This classification reflects the specialist nature of GLP-1 receptor agonists, the requirement for medical monitoring, and the potential for rare but serious adverse reactions. Unlike some over-the-counter treatments, semaglutide must be initiated under medical supervision with regular review of kidney function, pancreatic health, and glycaemic parameters.
Regulatory oversight
The UK Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorisation of semaglutide products. Marketing authorisations specify the indication, dosage forms, strengths, and pack sizes. Any change to legal classification or supply conditions requires MHRA review and consultation.
Importation and parallel supply
While UK-licensed semaglutide requires prescription, licensed parallel-imported and generic versions from EU countries may be available under the same POM classification. Some online pharmacies advertise “without prescription” supply; however, any lawful supply in the UK must respect POM regulations.
Mechanism of action
Semaglutide mimics endogenous GLP-1 by binding to the GLP-1 receptor on pancreatic β-cells, enhancing glucose-dependent insulin secretion. It also binds GLP-1 receptors on α-cells, suppressing glucagon release when glucose levels are elevated. Additionally, semaglutide slows gastric emptying via central and peripheral pathways and engages appetite-regulating circuits in the hypothalamus, promoting satiety. These mechanisms synergise to reduce hyperglycaemia and decrease caloric intake, driving weight loss.
Glucose-dependent insulinotropic effect
By amplifying insulin release only when blood glucose is high, semaglutide lowers the risk of hypoglycaemia compared with non-glucose-dependent secretagogues. This safety feature is a key advantage of GLP-1 RAs.
Effects on gastric motility
Delayed gastric emptying contributes to postprandial glycaemic control and early satiety. Patients often report reduced appetite and diminished food cravings, supporting weight-loss outcomes.
Neuroendocrine appetite regulation
Central GLP-1 receptors modulate appetite centres in the brain. Semaglutide’s action on these pathways affects reward circuits and food preferences, potentially improving long-term adherence to dietary changes.
Price and how to buy online
Semaglutide’s price in the UK varies by brand, pack size, dosage strength, and source. Branded formulations such as Ozempic® (for diabetes) and Wegovy® (for weight management) generally cost more than unbranded generics. Online pharmacies, including Markeaton Pharmacy, offer competitive prices on branded and generic semaglutide, often at a cheaper rate than high-street outlets.
Factors affecting price
Key determinants of semaglutide pricing include:
- Dosage strength (0.25 mg, 0.5 mg, 1 mg, 2 mg, 2.4 mg weekly);
- Pack size (4, 8, or 12 prefilled pens per pack);
- Manufacturer and brand versus generic status;
- Importation costs, shipping fees, and pharmacy mark-ups;
- Volume discounts and promotional offers.
How to order
To purchase semaglutide from Markeaton Pharmacy, complete our secure online form, choose your preferred strength and quantity, and select delivery options. A valid prescription must be uploaded or emailed. Non-UK prescriptions may be accepted under specific MHRA rules for private supply. We aim to dispatch orders within 48 hours of receipt of prescription and payment.
Cheaper generic semaglutide
Generic semaglutide maintains bioequivalence to branded products and can be significantly cheaper. Ask our pharmacy team for a quote on generic options to reduce overall treatment cost.
Available strengths and formulations
Semaglutide is available as a subcutaneous solution in prefilled pens. Each delivery device contains a fixed dose per injection. Common presentations include:
| Strength | Weekly dose | Pack size |
|---|---|---|
| 0.25 mg | Initiation dose, once weekly | 4 pens |
| 0.5 mg | Maintenance dose, once weekly | 4 or 8 pens |
| 1 mg | Escalation or maintenance, once weekly | 4 or 8 pens |
| 2 mg | Higher-dose maintenance, once weekly | 4 pens |
| 2.4 mg | Weight management, once weekly | 4 pens |
No oral formulations of semaglutide are licensed in the UK. Research into oral tablets is ongoing but remains investigational and is not available without prescription.
Administration and dosing
Semaglutide is self-administered once weekly on the same day each week, with or without meals. Injection sites may include the abdomen, thigh, or upper arm. Rotate sites to reduce irritation. Patients should follow the dosing schedule carefully and titrate the dose according to prescribing information: start at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg. Further escalation to 1 mg or 2 mg may occur based on glycaemic response and tolerability. For weight management, begin at 0.25 mg weekly and escalate through 0.5 mg, 1 mg, 1.7 mg to target 2.4 mg weekly.
Injection technique
Prepare the pen by attaching a new needle, prime according to instructions, select the correct dose, insert needle at a 90° angle, depress the plunger fully, hold for 5 seconds, then remove. Dispose of needles in a sharps bin.
Missed dose
If a dose is missed within 5 days of the scheduled day, administer as soon as possible. If more than 5 days have elapsed, skip the missed dose and resume the regular schedule. Do not double up doses.
Clinical efficacy and trials
Major clinical trials (SUSTAIN and STEP series) have established semaglutide’s efficacy. In type 2 diabetes, SUSTAIN trials showed mean HbA1c reductions of 1.5–1.8%, significant weight loss, and low hypoglycaemia rates. In obesity, STEP trials reported average weight loss of 10–15% over 68 weeks.
SUSTAIN programme
SUSTAIN 1–10 evaluated semaglutide 0.5 mg and 1 mg weekly in diverse populations with type 2 diabetes. Compared with placebo, exenatide, dulaglutide, and insulin glargine, semaglutide demonstrated superior glycaemic and weight-loss outcomes.
STEP weight-loss trials
STEP 1–8 assessed semaglutide 2.4 mg in obese or overweight adults. STEP 4 demonstrated sustained weight loss over 68 weeks, with mean reductions exceeding 12% of baseline weight. STEP 5 and STEP 6 extend findings to different demographics and treatment durations.
Real-world evidence
Observational studies and registry data confirm semaglutide’s effectiveness in routine clinical practice, with adherence rates favourable compared to other injectable therapies.
Safety, side effects and tolerability
Semaglutide is generally well tolerated. Common adverse events are gastrointestinal and include nausea, vomiting, diarrhoea, constipation, and abdominal pain. These effects are dose-dependent and often diminish over several weeks. Less common reactions include injection-site reactions and dizziness.
| System | Adverse events |
| Gastrointestinal | Nausea, vomiting, diarrhoea, constipation |
| Metabolic | Hypoglycaemia when combined with insulin or sulfonylureas |
| Skin | Injection-site erythema or pruritus |
| General | Fatigue, dizziness |
| Rare | Pancreatitis, gallbladder disease, acute kidney injury |
Pancreatitis warning
Reports of acute pancreatitis necessitate immediate discontinuation and medical evaluation if severe abdominal pain, with or without vomiting, occurs. Routine monitoring of pancreatic enzymes is not universally recommended but may be considered in high-risk patients.
Hypoglycaemia risk
When combined with insulin or insulin secretagogues, semaglutide may increase hypoglycaemia risk. Dose adjustments of concomitant therapies are advised.
Contraindications and interactions
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). It should be used with caution in those with a history of pancreatitis. Concomitant use with other GLP-1 RAs is not recommended.
Drug interactions
By delaying gastric emptying, semaglutide may alter absorption of oral medications. Monitor drugs with narrow therapeutic windows (e.g., warfarin, digoxin). No significant CYP-mediated interactions have been reported, but caution is advised when co-administering with medications requiring acidic pH for absorption.
Renal and hepatic impairment
No dose adjustment is required for mild to moderate renal or hepatic impairment. Severe impairment data are limited; monitor patients closely for adverse reactions.
Generic versus branded semaglutide
Generic semaglutide is bioequivalent to the branded originator but typically offered at a cheaper price. All generics must meet UK and EU quality, safety, and efficacy standards. Patients choosing generic semaglutide can expect the same clinical effects but with cost savings.
Quality assurance
Brands and generics undergo rigorous testing. Batch release tests, stability studies, and post-marketing surveillance ensure consistent potency and purity.
Buying without prescription
Despite some online claims, semaglutide remains POM in the UK. Any legitimate supply requires a prescription. Beware of unlicensed sites offering “purchase without prescription,” as these may supply counterfeit or substandard products, posing significant health risks.
Risks of unregulated purchase
Counterfeit semaglutide may contain incorrect dose, harmful impurities, or no active ingredient. Always buy from MHRA-regulated pharmacies.
Fast delivery and shipping
Markeaton Pharmacy provides tracked next-day delivery across mainland UK for semaglutide orders. Orders received with valid prescription by 3 pm Monday to Friday are dispatched same day. Delivery to Northern Ireland, Scottish Highlands, and offshore UK areas may take 2–3 days. Temperature-controlled packaging ensures product integrity.
International shipping
We do not ship semaglutide outside the UK due to regulatory restrictions. UK residents abroad please contact customer support for guidance on local legal supply options.
Storage and handling
Store semaglutide pens in a refrigerator between 2°C and 8°C. Do not freeze. Keep away from light. After first use, pens may be kept at temperatures up to 30°C or in a refrigerator for up to 6 weeks. Always follow the manufacturer’s instructions. Do not store with the needle attached.
Disposal
Dispose of used needles in a dedicated sharps bin. Return full sharps bins to your pharmacy or local medical waste disposal site. Do not discard needles in household waste.
FAQs and additional information
Can I use semaglutide if I am pregnant or breastfeeding?
Semaglutide is not recommended during pregnancy or breastfeeding due to lack of safety data. Women planning pregnancy should discontinue treatment and consult healthcare providers.
How long does it take to see effects?
Glycaemic improvements can be seen within weeks, with significant effects on HbA1c after 12–16 weeks. Weight loss may begin within 4 weeks and continues over months.
Does semaglutide interact with alcohol?
Alcohol can exacerbate gastrointestinal side effects and affect glycaemic control. Moderate alcohol consumption is advised, with regular blood glucose monitoring.
Where can I get more information?
Consult the MHRA website, the electronic Medicines Compendium (eMC), and qualified healthcare professionals. Markeaton Pharmacy staff can answer queries tailored to your situation.